Sam Brusco, Associate Editor01.26.23
Abbott Labs has gained U.S. Food and Drug Administration (FDA) approval for its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN).
The Proclaim XR SCS provides an alternative to traditional treatment approaches like oral medication. Those receiving therapy from the system also have access to Abbott’s NeuroSphere virtual clinic, a connected care app for people to communicate with a physician and receive remote treatment adjustments.
Proclaim XR SCS’ battery lasts up to 10 years at low-dose settings, according to Abbott.
"Diabetic peripheral neuropathy has long plagued people affected by type 1 and type 2 diabetes, often adding another area of disease management on top of their ongoing monitoring of their glucose levels to manage this challenging disease," Jason E. Pope, MD, DABPM, FIPP, president of Evolve Restorative Center in Santa Rosa, Calif told the press. "Abbott's Proclaim XR spinal cord stimulation system provides patients with painful diabetic peripheral neuropathy the opportunity to obtain a better quality of life while more seamlessly fitting into their current lifestyles."
Patients can control their therapy with an Apple device, which can also be programmed using the NeuroSphere virtual clinic technology.
"As a leader in diabetes care, Abbott is intimately familiar with the challenges people with diabetes encounter daily. This new indication for Proclaim XR will drive meaningful change in the treatment of pain associated with diabetic peripheral neuropathy and will be an important tool for physicians and patients in managing this debilitating condition," said Pedro Malha, vice president, neuromodulation, Abbott.
The Proclaim XR SCS provides an alternative to traditional treatment approaches like oral medication. Those receiving therapy from the system also have access to Abbott’s NeuroSphere virtual clinic, a connected care app for people to communicate with a physician and receive remote treatment adjustments.
Proclaim XR SCS’ battery lasts up to 10 years at low-dose settings, according to Abbott.
"Diabetic peripheral neuropathy has long plagued people affected by type 1 and type 2 diabetes, often adding another area of disease management on top of their ongoing monitoring of their glucose levels to manage this challenging disease," Jason E. Pope, MD, DABPM, FIPP, president of Evolve Restorative Center in Santa Rosa, Calif told the press. "Abbott's Proclaim XR spinal cord stimulation system provides patients with painful diabetic peripheral neuropathy the opportunity to obtain a better quality of life while more seamlessly fitting into their current lifestyles."
Patients can control their therapy with an Apple device, which can also be programmed using the NeuroSphere virtual clinic technology.
"As a leader in diabetes care, Abbott is intimately familiar with the challenges people with diabetes encounter daily. This new indication for Proclaim XR will drive meaningful change in the treatment of pain associated with diabetic peripheral neuropathy and will be an important tool for physicians and patients in managing this debilitating condition," said Pedro Malha, vice president, neuromodulation, Abbott.